GlassScriptPhysician profile
Wendy G Pearce
NPI 1073968574
$1,853.82
in general payments reported to CMS, 2019-2025
20 companies · $707 in 2025
The $707 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $256 · 2023: $268 · 2024: $507 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.02 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $317.18 | 2021-2025 | |
| Corcept Therapeutics | $208.16 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $187.36 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $139.03 | 2024-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $124.94 | 2022-2025 | |
| Qol Medical, LLC | $73.70 | 2025 | Sucraid |
| Lilly USA, LLC | $70.17 | 2021-2025 | Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $61.22 | 2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.35 | 2023 | Ofev, Jardiance |
| Pfizer INC. | $48.98 | 2023-2025 | |
| Glaxosmithkline, LLC. | $48.05 | 2021-2024 | Trelegy Ellipta |
| Dexcom, INC. | $40.00 | 2022 | |
| Biocryst US Sales Co., LLC | $36.44 | 2021-2022 | |
| Pharming Healthcare, INC. | $33.68 | 2022-2024 | Ruconest |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $26.57 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $15.78 | 2024 | Contrave |
| Cycle Pharmaceuticals INC | $14.85 | 2025 | Sajazir |
| Biohaven Pharmaceutical Holding Company LTD. | $14.53 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Pearce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.